tiprankstipranks
Trending News
More News >
SelectQuote (SLQT)
NYSE:SLQT

SelectQuote (SLQT) AI Stock Analysis

Compare
406 Followers

Top Page

SLQT

SelectQuote

(NYSE:SLQT)

Select Model
Select Model
Select Model
Neutral 54 (OpenAI - 5.2)
Rating:54Neutral
Price Target:
$2.00
▲(29.87% Upside)
The score is held back primarily by challenged cash generation (negative operating cash flow) and thin profitability, despite improvements in gross margin and leverage. Technically, shares show short-term strength but remain below longer-term averages with momentum indicators not fully supportive. Valuation is difficult given the negative P/E, while the earnings call and new credit facility add some support via maintained outlook and improved liquidity.
Positive Factors
Improved liquidity from new credit facility
The $415M senior secured facility lengthens debt maturity to 2031, raises revolver capacity and reduces amortization. This structurally strengthens liquidity and gives multi-year breathing room to execute operational fixes, fund seasonality, and convert improving margins into sustained cash flow.
Sustained gross margin improvement
Gross margin rising to ~61% from mid-40s reflects material cost and mix improvements that enhance operating leverage. If retained, higher gross margins provide a durable buffer to absorb SG&A volatility and support long-term cash generation and reinvestment into growth initiatives.
Diversified growth outside Senior segment
Nearly 20% Life insurance revenue growth and 13% consolidated growth indicate diversification beyond Medicare-driven Senior sales. Strong Life and Healthcare Services momentum can reduce dependence on a single policy stream, stabilizing commissions and supporting multi-channel cross-sell opportunities.
Negative Factors
Negative operating cash flow
Negative operating cash flow in the trailing period signals cash conversion weaknesses despite improving gross margins. Persistent OCF deficits would limit internal funding for marketing and agent capacity, increase reliance on debt or receivable-backed financing, and constrain long-term value creation.
Sharp Senior segment revenue decline
A 37% Senior revenue drop and 32% fewer policies from eligibility changes undermine the core Medicare-focused business that drives most commissions. Structural or regulatory shifts that reduce enrollments pose a durable earnings risk and make revenue recovery dependent on policy and enrollment normalization.
Contractual reimbursement risk (PBM)
A ~$20M EBITDA headwind from PBM reimbursement changes highlights exposure to third-party contract terms. Dependence on PBM pricing and reimbursement creates ongoing margin volatility risk for Healthcare Services until long-term agreements are secured and could materially affect sustained profitability.

SelectQuote (SLQT) vs. SPDR S&P 500 ETF (SPY)

SelectQuote Business Overview & Revenue Model

Company DescriptionSelectQuote, Inc. operates a technology-enabled, direct-to-consumer distribution platform that sells a range of insurance policies to consumers from various insurance carriers in the United States. The company operates through three segments: Senior; Life; and Auto & Home. It distributes senior health policies, such as medicare advantage, medicare supplement, medicare part D, and other ancillary senior health insurance related policies, including prescription drugs, dental, vision, and hearing plans; term life policies; and non-commercial auto and home property, and casualty policies. The company was incorporated in 1999 and is headquartered in Overland Park, Kansas.
How the Company Makes MoneySelectQuote generates revenue primarily through commissions earned on the sale of insurance policies. The company partners with numerous insurance carriers, receiving a commission for each policy sold through its platform. This commission-based model allows SelectQuote to monetize its extensive customer base effectively. Additionally, the company may earn referral fees for directing customers to specific insurance providers. SelectQuote's focus on providing a transparent and user-friendly experience attracts a wide audience, contributing to its revenue growth. The company also invests in marketing and technology to enhance its services and expand its reach within the insurance marketplace.

SelectQuote Earnings Call Summary

Earnings Call Date:Nov 06, 2025
(Q1-2026)
|
% Change Since: |
Next Earnings Date:Feb 09, 2026
Earnings Call Sentiment Neutral
SelectQuote experienced both positive and negative trends during the fiscal first quarter. The company achieved significant revenue growth in its consolidated and Life Insurance business, alongside operational achievements with the new Kansas facility. However, it faced challenges with declines in Senior segment revenues due to policy changes and a significant EBITDA impact in Healthcare Services caused by reimbursement rate adjustments. These challenges have led to unmet fiscal targets, impacting overall sentiment.
Q1-2026 Updates
Positive Updates
Consolidated Revenue Growth
SelectQuote generated consolidated revenue of $329 million, representing a 13% growth over the same period a year ago, driven by strong growth in Healthcare Services.
Life Insurance Business Growth
Revenues expanded nearly 20% in the Life Insurance segment, driven by balanced growth in term life and final expense policies.
New Kansas Facility
The new Kansas facility is ramping as planned, delivering efficiency gains in line with expectations.
SelectRx Clinical Value
SelectRx improves medication adherence and health outcomes, reducing hospital days by around 20% for members, which benefits the healthcare system.
Negative Updates
Senior Revenue Decline
Senior revenues were $59 million compared to $93 million a year ago, driven by a 32% fewer policies due to changes in beneficiary eligibility requirements.
Healthcare Services EBITDA Impact
First quarter Healthcare Services EBITDA was impacted by a change in drug reimbursement rates with a SelectRx PBM partner, affecting the first half of the fiscal year by approximately $20 million.
Consolidated EBITDA Loss
Quarterly EBITDA was negative $32 million, below the guided loss range of $25 million to $30 million due to SelectRx margin dynamics.
Unmet Fiscal Targets
SelectQuote no longer anticipates reaching its $50 million EBITDA target for fiscal '26, aiming instead for an annualized run rate of $40 million to $50 million by year-end.
Company Guidance
During the SelectQuote fiscal first quarter earnings call, several key metrics and guidance were highlighted. The company reported consolidated revenue of $329 million, marking a 13% year-over-year increase, primarily driven by growth in Healthcare Services. However, the Senior segment experienced a 37% decline in revenue to $59 million due to changes in beneficiary eligibility requirements during the special election period, leading to a negative EBITDA of $21 million. Despite this, the company is optimistic about the upcoming Annual Enrollment Period (AEP) and expects to exit fiscal 2026 with an annualized EBITDA run rate between $40 million and $50 million. Additionally, SelectQuote faced a $20 million headwind in Healthcare Services due to a change in drug reimbursement rates from a pharmacy benefit manager (PBM) partner, impacting first and second quarter EBITDA margins. The company remains confident in reaching a longer-term agreement with the PBM, expecting normalized reimbursement rates by January 1, 2026. Overall, SelectQuote maintained its fiscal 2026 financial outlook, projecting revenues of $1.65 billion to $1.75 billion and adjusted EBITDA between $120 million and $150 million, with expectations to be operating cash flow positive for the year.

SelectQuote Financial Statement Overview

Summary
SelectQuote shows signs of recovery with improved revenue growth and gross profit margins. However, profitability remains a concern with low net profit margins and negative operating cash flow. The reduction in leverage is a positive sign, but the company needs to address cash flow challenges to ensure long-term financial health.
Income Statement
65
Positive
SelectQuote has shown a positive revenue growth trend with a TTM revenue growth rate of 2.39%. The gross profit margin has improved significantly from 45.24% in 2024 to 61.30% in TTM, indicating better cost management. However, the net profit margin remains low at 3.12% in TTM, suggesting limited profitability. The EBIT and EBITDA margins have improved but are still modest, reflecting operational challenges.
Balance Sheet
58
Neutral
The company's debt-to-equity ratio has improved to 0.17 in TTM from a high of 2.25 in 2024, indicating reduced leverage and better financial stability. However, the return on equity is relatively low at 11.01% in TTM, suggesting limited returns for shareholders. The equity ratio is not provided, which limits a full assessment of asset financing.
Cash Flow
50
Neutral
SelectQuote's cash flow situation is challenging, with negative operating cash flow in TTM. The free cash flow growth rate is positive at 40.62% in TTM, but the operating cash flow to net income ratio is negative, indicating cash flow issues. The free cash flow to net income ratio is strong at 1.19, suggesting efficient cash generation relative to net income.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue1.56B1.53B1.32B1.00B764.04M929.98M
Gross Profit723.36M591.13M597.97M475.36M308.35M659.27M
EBITDA133.19M148.36M89.48M39.34M-321.49M203.48M
Net Income61.67M47.58M-34.13M-58.54M-297.50M124.86M
Balance Sheet
Total Assets1.21B1.25B1.19B1.22B1.29B1.42B
Cash, Cash Equivalents and Short-Term Investments10.74M32.40M42.69M83.16M141.00M286.45M
Total Debt422.85M415.91M713.92M731.80M745.06M505.30M
Total Liabilities660.05M673.84M877.11M872.28M898.95M756.82M
Stockholders Equity546.93M575.52M316.80M346.97M391.11M667.04M
Cash Flow
Free Cash Flow-24.39M-13.86M3.57M-28.50M-372.96M-138.43M
Operating Cash Flow-16.68M-11.67M15.24M-19.38M-338.31M-115.44M
Investing Cash Flow-12.72M-11.31M-14.85M-9.13M-42.58M-64.02M
Financing Cash Flow34.66M17.36M-40.86M-29.34M235.43M97.04M

SelectQuote Technical Analysis

Technical Analysis Sentiment
Positive
Last Price1.54
Price Trends
50DMA
1.48
Positive
100DMA
1.78
Negative
200DMA
2.11
Negative
Market Momentum
MACD
0.01
Negative
RSI
55.20
Neutral
STOCH
61.11
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SLQT, the sentiment is Positive. The current price of 1.54 is above the 20-day moving average (MA) of 1.41, above the 50-day MA of 1.48, and below the 200-day MA of 2.11, indicating a neutral trend. The MACD of 0.01 indicates Negative momentum. The RSI at 55.20 is Neutral, neither overbought nor oversold. The STOCH value of 61.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SLQT.

SelectQuote Risk Analysis

SelectQuote disclosed 54 risk factors in its most recent earnings report. SelectQuote reported the most risks in the "Production" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

SelectQuote Peers Comparison

Overall Rating
UnderperformOutperform
Sector (68)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
68
Neutral
$18.00B11.429.92%3.81%9.73%1.22%
58
Neutral
$115.98M101.625.88%16.79%
54
Neutral
$271.00M-51.5115.11%13.16%
46
Neutral
$22.80M9.074.56%19.30%-17.56%
44
Neutral
$36.53M-0.14-142.05%7.56%-344.04%
44
Neutral
$5.12M-0.22-146.43%-6.84%97.23%
43
Neutral
$13.58M-0.12-11.18%624.24%85.46%
* Financial Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SLQT
SelectQuote
1.54
-2.62
-62.98%
EHTH
Ehealth
3.77
-6.12
-61.88%
RELI
Reliance Global Group
0.52
-1.57
-75.11%
HUIZ
Huize Holding
2.26
-0.79
-25.90%
TIRX
Tian Ruixiang Holdings
0.51
-7.79
-93.82%
GOCO
GoHealth
2.27
-11.25
-83.21%

SelectQuote Corporate Events

Business Operations and StrategyPrivate Placements and Financing
SelectQuote secures new $415 million credit facility
Positive
Jan 12, 2026

On January 8, 2026, SelectQuote entered into a new $415 million senior secured credit facility consisting of a $325 million term loan led by Pathlight Capital and a $90 million revolving credit facility with UMB Bank, using roughly $313.8 million of the term loan proceeds to fully repay its prior debt and cover transaction costs. Announced publicly on January 12, 2026, the financing significantly extends the company’s debt maturity to January 2031, modestly lowers its cost of capital, increases peak-season revolver capacity from $72 million to $90 million, and reduces principal amortization requirements, collectively strengthening liquidity and operational flexibility as the company looks to leverage its roughly $1 billion in commissions receivable and the growing cash generation of its SelectRx and healthcare services operations, while its obligations remain secured by substantially all company and guarantor subsidiary assets and subject to customary covenants, coverage ratios, and borrowing-base tests tied to receivables.

The most recent analyst rating on (SLQT) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on SelectQuote stock, see the SLQT Stock Forecast page.

Executive/Board ChangesShareholder Meetings
SelectQuote Holds 2025 Annual Stockholders Meeting
Neutral
Nov 14, 2025

On November 11, 2025, SelectQuote, Inc. held its 2025 Annual Meeting of Stockholders, where 114,443,928 shares were represented. During the meeting, two Class III directors were elected, Deloitte & Touche LLP was ratified as the independent accounting firm for the fiscal year ending June 30, 2026, and the compensation for the company’s named executive officers was approved.

The most recent analyst rating on (SLQT) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on SelectQuote stock, see the SLQT Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jan 13, 2026